[Clinical and experimental animal study results on the problem of the expediency of supplementary use of lactoflavin within the scope of isonicotinic hydrazide therapy].
D032761:Animal Experimentation; D000818:Animals; D000900:Anti-Bacterial Agents; D007538:Isoniazid / Q000628:therapy*; D012256:Riboflavin / Q000628:therapy*
D000900:Anti-Bacterial Agents; D012256:Riboflavin; D007538:Isoniazid
ISONIAZID/therapy; VITAMIN B 2/therapy